Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267069 · ClinicalTrials.gov registry record
Evaluating Alcohol Use in Alcoholic Liver Disease
A clinical trial of Alcoholic Liver Disease, sponsored by Nicole T Shen.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT03267069: Recruiting study of Alcoholic Liver Disease, sponsored by Nicole T Shen.
NCT03267069 is a study of Alcoholic Liver Disease that is actively recruiting participants, run by Nicole T Shen. The registered enrollment target is 160 participants, above the 45-participant average among 5 other Alcoholic Liver Disease trials with a reported enrollment target (256% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03267069, a study of Alcoholic Liver Disease, is actively recruiting participants, sponsored by Nicole T Shen.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective, analytic observational study will investigate alcohol recidivism in patients with alcoholic liver disease. All adult subjects presenting with alcoholic liver disease are considered for inclusion. Subjects able to give consent are included.
Primary Outcome
Follow-up questionnaires will be administered at 6 months assessing for alcohol use
Conditions Studied
Interventions
- OTHER survey
Study Locations (1)
New York
- New York Presbyterian Hospital - Weill Cornell Medicine and Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2016-11-27 |
| Est. Completion | 2027-11-01 |
What NCT03267069 shows while recruiting
NCT03267069 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 45-participant average among 5 other Alcoholic Liver Disease trials with a reported enrollment target (256% higher).
The record links to 1 condition, with Alcoholic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which survey is the first listed.
NCT03267069 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03267069 about?
NCT03267069 is a clinical study titled "Evaluating Alcohol Use in Alcoholic Liver Disease". This prospective, analytic observational study will investigate alcohol recidivism in patients with alcoholic liver disease. All adult subjects presenting with alcoholic liver disease are considered for inclusion. Subjects able to give consent are included.
What is the current status of trial NCT03267069?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2016-11-27. Estimated completion is 2027-11-01.
What conditions does trial NCT03267069 study?
This clinical trial studies the following conditions: Alcoholic Liver Disease.
What interventions are being tested in trial NCT03267069?
The interventions under investigation include: survey (OTHER).
Who is sponsoring clinical trial NCT03267069?
This trial is sponsored by Nicole T Shen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03267069 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholic Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
RECRUITING · NA
-
Ethanol Induces Skeletal Muscle Autophagy
RECRUITING
-
Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)
ACTIVE NOT RECRUITING
-
Alcoholic Liver Disease and the Gut Microbiome
ACTIVE NOT RECRUITING · NA
-
A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI